Date:3/18/2013

ondition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions, developments and other investments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with downturns in foreign, domestic and local economies, changes in interest rates and foreign currency exchange rates, and volatility in the securities markets; ownership of properties outside of the United States that subject the company to different and potentially greater risks than those associated with the company's domestic operations; risks associated with the company's investments in loans, including borrower defaults and potential principal losses; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statemen
'/>"/>

SOURCE BioMed Realty Trust, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
2. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
3. Lupus Research Institute Requests Strengthened NIH Funding for Biomedical Research in Debilitating Diseases like Lupus
4. Fourth Annual Bay Area Biomedical Device Conference: March 27th, 2013 at San Jose State University
5. Foundation for the NIH Announces Lurie Prize Recognizing Outstanding Achievement by a Young Biomedical Scientist
6. Lou Paradise, President and Chief of Research, Topical BioMedics, Inc. Slated to Speak at Integrative Healthcare Symposium
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
9. BioMed Realty Trust Prices Public Offering Of 12,700,000 Shares Of Common Stock
10. ABIA Hires Biomedical Executive, Serial Entrepreneur as Chief Operating Officer
11. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th